5 studies found for:    ventirx
Show Display Options
Rank Status Study
1 Not yet recruiting A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX® (Cetuximab) and VTX-2337
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: VTX-2337;   Drug: Cetuximab
2 Active, not recruiting VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: pegylated liposomal doxorubicin (PLD);   Drug: VTX-2337;   Drug: Placebo
3 Completed Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
Conditions: Advanced Solid Tumors;   Lymphoma
Intervention: Drug: VTX-2337
4 Terminated VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
Condition: Low Grade B Cell Lymphoma
Intervention: Drug: VTX-2337 plus radiotherapy
5 Recruiting Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Carcinoma, Squamous Cell of Head and Neck
Interventions: Drug: VTX-2337;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fluorouracil;   Drug: Placebo

Indicates status has not been verified in more than two years